ARTICLE | Clinical News
Arzerra ofatumumab regulatory update
July 20, 2015 7:00 AM UTC
Novartis submitted an application to EMA to expand the label of Arzerra ofatumumab to include maintenance treatment of relapsed chronic lymphocytic leukemia (CLL). The human mAb against CD20 is approv...